Overview

* Sensus Healthcare Q3 2025 revenue of $6.9 mln beats analyst expectations

* Net loss for Q3 2025 was $0.9 mln, reflecting operational challenges

* Adjusted EBITDA for Q3 2025 missed analyst estimates

Outlook

* Company sees strong interest internationally following MDSAP certification

* CMS coding expected to strengthen SRT adoption and reimbursement certainty

Result Drivers

* INCREASED TREATMENT VOLUME - FDA treatment volumes rose 20% over the second quarter, reflecting growing adoption

* INTERNATIONAL EXPANSION - Shipped 16 SRT systems, including three to China, and preparing for broader expansion

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $6.88 $6.25

Revenue mln mln (5

Analysts

)

Q3 Net -$943,00

Income 0

Q3 Miss -$2.40 -$485,00

Adjusted mln 0 (2

EBITDA Analysts

)

Q3 Basic -$0.06

EPS

Q3 $5.28

Operatin mln

g

Expenses

Q3 -$2.41

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Sensus Healthcare Inc ( SRTS ) is $8.00, about 53.9% above its November 5 closing price of $3.69

* The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)